Revatio (sildenafil) should not be prescribed to children and adolescents with pulmonary arterial hypertension, according to an FDA MedWatch alert. The warning is based on the results of a trial published in Circulation that showed increased mortality at medium and high doses of Revatio, compared with low-dose treatment, among patients aged 1 to 17 years….

This content is exclusive to CardioExchange. To continue reading, please log in or request an invitation.

James H. Stein, MD sounds a clarion about the influence of the medical industry on the debate over whether children should be universally screened for dyslipidemia, as recommended by recent guidelines.

The FDA has identified more than 100 cases of cardiac erosion following atrial septal defect occlusion (ASO) device implantation. All were associated with implantation of the AMPLATZER (AGA Medical/St. Jude Medical) or related cribriform ASO devices; none have been reported thus far with the GORE HELEX (Gore Medical) ASO device. Although the estimated occurrence of cardiac…

This content is exclusive to CardioExchange. To continue reading, please log in or request an invitation.